USE YOUR BRAIN:
NEWS--- PPS UP--- ARMISTICE OUT IN GAIN
It's quite clear that Armistice had his "easy way" from Raj to exit and stop writing letters...
The rapid hemodynamic stabilization with reduction of vasopressor needs within hours and reduction of the capillary leakage as well as a quick reduction in infection markers were the main conclusions drawn from the use of CytoSorb in this patient. Additionally, treatment appeared to be safe and was well tolerated. Despite the promising results of CytoSorb application in this patient, further studies are necessary to elucidate to what extent these favorable consequences are attributable to the adsorber itself.
• Accepted on 05/08/2015
• Available online on 31/08/2015
Financial support: There was no financial support for this study.
Conflict of interest: None of the authors have any conflicts of interest associated with this report.
CytoSorb, a novel therapeutic approach for patients with septic shock: a case report
Post author correction
Article Type: SHORT COMMUNICATION
Article Subject: Artificial kidney, apheresis and detoxification techniques
Burkhard Hinz, Oliver Jauch, Toralf Noky, Sigrun Friesecke, Peter Abel, Rolf Kaiser
Friedrich-Trendelenburg-Allee 1, 18273 Güstrow, Germany
Hemoadsorption using CytoSorb has gained attention as a potential immunotherapy to control systemic inflammation and sepsis. We report on a patient with septic shock, successfully treated with CytoSorb therapy.
A 72-year-old male with periodically recurring infectious episodes was admitted with the suspicion of urosepsis. In the following hours his hemodynamic situation deteriorated markedly, exhibiting respiratory-metabolic acidosis, elevated inflammatory marker plasma levels, a severely disturbed coagulation, increased retention parameters, liver dysfunction, and confirmation of bacteria and leucocytes in urine. After admission to the ICU in a state of septic shock the patient received renal support with additional hemoadsorption using CytoSorb. Three CytoSorb sessions were run during the following days.
The first and consecutive second session resulted in a reduction of procalcitonin, C-reactive protein and bilirubin and a markedly reduced need for vasopressors while hemodynamics improved significantly (i.e., cardiac index, extravascular lung water). Due to a recurring inflammatory “second hit” episode, another session with CytoSorb was run, resulting in a marked decrease in leukocytosis and liver (dys)function parameters.
The rapid hemodynamic stabilization with reduction of vasopressor needs within hours and reduction of the capillary leakage as well as a quick reduction in infection markers were the main conclusions drawn from the use of CytoSorb in this patient. Addi
MONMOUTH JUNCTION, N.J., April 27, 2015 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® extracorporeal cytokine adsorber to purify blood and control severe inflammation, announced the appointment of Dr. Joerg Scheier, M.D. as European Medical Director.
Dr. Scheier is a specialist in intensive care medicine and anesthesiology, with more than 15 years of combined experience in treating critically-ill patients and in the design and execution of clinical trials in critical care and cardiac medical devices in Germany. Dr. Scheier joins CytoSorbents from SORIN Group, a global leader in cardiac surgery, where he served as Country Manager of Clinical Operations in Germany and led the implementation of SORIN's international clinical development and operations strategy in the country.
Part 1 completed. Dates tell clearly that part 2 probably did not started due to insufficient efficacy.
The odd thing is that clinical trials was not updated in a clear manner, so that it was clear that trial stopped. If so, it's something very very fishy… but with Raj it's quite normal
I review the trial data and dates on clinical trials: i would say that trial stopped after part I enrollment and probably did non continued. I hope it's not so, but watching dates it is very probable.
So, i don't understand: when was the last time Raj talked about SPI-1620? The last Q2 Conf? Are you saying he mentioned it but without saying the name?